LTC2924034I2 - Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių - Google Patents

Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Info

Publication number: LTC2924034I2
Authority: LT; Lithuania
Prior art keywords: pharmaceutical composition; reverse transcriptase; nucleoside reverse; transcriptase inhibitor; nucleoside
Prior art date: 2010-03-30

Application number

LTPA2019507C

Other languages

English (en)

Original Assignee

Merck Canada Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-30

Filing date

2019-04-11

Publication date

2020-10-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2924034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-04-11 Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.

2019-04-25 Publication of LTPA2019507I1 publication Critical patent/LTPA2019507I1/lt

2020-10-12 Publication of LTC2924034I2 publication Critical patent/LTC2924034I2/lt

Links

229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTPA2019507C 2010-03-30 2019-04-11 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių LTC2924034I2 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31882410P	2010-03-30	2010-03-30
US32157310P	2010-04-07	2010-04-07
EP11761856.1A EP2552902B1 (en)	2010-03-30	2011-03-28	Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number	Publication Date
LTPA2019507I1 LTPA2019507I1 (lt)	2019-04-25
LTC2924034I2 true LTC2924034I2 (lt)	2020-10-12

Family

ID=44710363

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP15157348.2T LT2924034T (lt)	2010-03-30	2011-03-28	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
LTPA2019507C LTC2924034I2 (lt)	2010-03-30	2019-04-11	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
LTPA2019506 LTC2552902I2 (lt)	2010-03-30	2019-04-11	Nenukleozidinės reversinės transkriptazės inhibitoriai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP15157348.2T LT2924034T (lt)	2010-03-30	2011-03-28	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2019506 LTC2552902I2 (lt)	2010-03-30	2019-04-11	Nenukleozidinės reversinės transkriptazės inhibitoriai

Country Status (44)

Country	Link
US (2)	US8486975B2 (lt)
EP (2)	EP2552902B1 (lt)
JP (2)	JP5281718B2 (lt)
KR (1)	KR101421861B1 (lt)
CN (1)	CN102971308B (lt)
AR (1)	AR080859A1 (lt)
AU (1)	AU2011235568B2 (lt)
BR (1)	BR112012024691B1 (lt)
CA (1)	CA2794377C (lt)
CL (1)	CL2012002744A1 (lt)
CO (1)	CO6630126A2 (lt)
CR (1)	CR20120503A (lt)
CY (3)	CY1118774T1 (lt)
DK (2)	DK2552902T3 (lt)
DO (1)	DOP2012000256A (lt)
EA (1)	EA024804B1 (lt)
EC (1)	ECSP12012201A (lt)
ES (2)	ES2609636T3 (lt)
FI (1)	FIC20190021I1 (lt)
GE (1)	GEP20156368B (lt)
HN (1)	HN2012002039A (lt)
HR (2)	HRP20150427T1 (lt)
HU (4)	HUE025336T2 (lt)
IL (2)	IL222030A (lt)
LT (3)	LT2924034T (lt)
LU (2)	LUC00114I2 (lt)
MA (1)	MA34170B1 (lt)
ME (2)	ME02570B (lt)
MX (1)	MX2012011379A (lt)
MY (1)	MY163979A (lt)
NI (1)	NI201200146A (lt)
NL (1)	NL300980I2 (lt)
NO (2)	NO2019019I1 (lt)
NZ (1)	NZ602670A (lt)
PE (1)	PE20130158A1 (lt)
PH (1)	PH12012501923A1 (lt)
PL (2)	PL2552902T3 (lt)
PT (2)	PT2552902E (lt)
RS (2)	RS55505B1 (lt)
SG (1)	SG184347A1 (lt)
SI (2)	SI2924034T1 (lt)
TN (1)	TN2012000455A1 (lt)
TW (1)	TWI458719B (lt)
WO (1)	WO2011120133A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102971308B (zh) *	2010-03-30	2015-02-04	默克加拿大有限公司	非核苷类逆转录酶抑制剂
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
EP2900240B1 (en) *	2012-09-26	2020-01-08	Merck Sharp & Dohme Corp.	Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
MX355439B (es) *	2012-12-05	2018-04-18	Merck Sharp & Dohme	Proceso para preparar inhibidores de la transcriptasa inversa.
MX375870B (es) *	2013-11-22	2025-03-07	Merck Sharp & Dohme Llc	Composicion de un inhibidor de la transcriptasa inversa sin nucleosido.
CA2930585A1 (en)	2013-12-04	2015-06-11	Merck Sharp & Dohme Corp.	Process for making reverse transcriptase inhibitors
RU2693622C2 (ru)	2014-04-01	2019-07-03	Мерк Шарп И Доум Корп.	Пролекарственные средства ингибиторов обратной транскриптазы вич
EP3760208B1 (en)	2014-06-25	2024-05-29	The General Hospital Corporation	Targeting human satellite ii (hsatii)
RU2736941C2 (ru)	2015-12-02	2020-11-23	Мерк Шарп энд Доум Корп.	Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
WO2018175271A1 (en) *	2017-03-24	2018-09-27	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
JP2020517633A (ja)	2017-04-18	2020-06-18	シプラ・リミテッド	レトロウイルス感染の治療に用いる併用療法
US20210213041A1 (en)	2018-02-06	2021-07-15	The General Hospital Corporation	Repeat rna as biomarkers of tumor immune response
US12005072B2 (en)	2018-07-17	2024-06-11	Merck Sharp & Dohme Llc	HIV drug combination for increasing barrier against resistance
MA54549A (fr)	2018-12-18	2022-03-30	Merck Sharp & Dohme	Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
CN110801455B (zh) *	2019-11-12	2020-06-02	河北医科大学第二医院	用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) *	2021-12-27	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体的制备方法
CN114349690B (zh) *	2022-02-15	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体合成方法
CN116903590A (zh) *	2023-06-06	2023-10-20	延边大学	一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) *	2023-12-15	2025-06-17	山东诚创蓝海医药科技有限公司	多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) *	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
EP1608629A1 (en)	2003-03-24	2005-12-28	F. Hoffmann-La Roche Ag	Benzyl-pyridazinons as reverse transcriptase inhibitors
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
DK1742908T3 (da)	2004-04-23	2010-01-18	Hoffmann La Roche	Ikke nukleosid revers transkriptase inhibitorer
EP1831157A2 (en)	2004-12-22	2007-09-12	Pfizer Limited	Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0617720A2 (pt)	2005-10-19	2011-08-02	Hoffmann La Roche	compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
ES2320042T3 (es)	2005-10-19	2009-05-18	F. Hoffmann-La Roche Ag	Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
AU2008326784B2 (en)	2007-11-20	2014-04-24	Merck Sharp & Dohme Corp.	Non-nucleoside reverse transcriptase inhibitors
CN102971308B (zh) *	2010-03-30	2015-02-04	默克加拿大有限公司	非核苷类逆转录酶抑制剂

2011
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
2012
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
2019
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I1/el unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I1/el unknown

Also Published As

Publication number	Publication date
RS55505B1 (sr)	2017-05-31
GEP20156368B (en)	2015-09-25
LTC2552902I2 (lt)	2019-12-10
ME02181B (me)	2015-10-20
EP2924034A1 (en)	2015-09-30
HUE031785T2 (en)	2017-08-28
CY2019025I2 (el)	2019-11-27
HK1209121A1 (en)	2016-03-24
HUS1900022I1 (hu)	2019-05-28
IL233334A (en)	2015-09-24
CO6630126A2 (es)	2013-03-01
HN2012002039A (es)	2015-08-24
LT2924034T (lt)	2016-12-27
CA2794377A1 (en)	2011-10-06
LUC00113I2 (lt)	2024-05-22
CY1118774T1 (el)	2017-07-12
PH12012501923A1 (en)	2013-02-04
US20110245296A1 (en)	2011-10-06
ECSP12012201A (es)	2012-10-30
MX2012011379A (es)	2012-11-30
EA201290976A1 (ru)	2013-03-29
CN102971308A (zh)	2013-03-13
ME02570B (me)	2017-06-20
TWI458719B (zh)	2014-11-01
EP2552902B1 (en)	2015-03-11
SG184347A1 (en)	2012-11-29
PT2924034T (pt)	2017-01-06
EA024804B1 (ru)	2016-10-31
FIC20190021I1 (fi)	2019-04-17
EP2552902A1 (en)	2013-02-06
IL233334A0 (en)	2014-09-01
PL2924034T3 (pl)	2017-07-31
KR101421861B1 (ko)	2014-07-22
AR080859A1 (es)	2012-05-16
NL300980I2 (nl)	2021-06-17
CA2794377C (en)	2015-06-16
DOP2012000256A (es)	2012-12-15
JP5281718B2 (ja)	2013-09-04
NO2019019I1 (no)	2019-04-24
HK1175471A1 (en)	2013-07-05
AU2011235568B2 (en)	2013-09-12
DK2552902T3 (en)	2015-06-15
HUS1900021I1 (hu)	2019-05-28
EP2552902A4 (en)	2013-09-04
DK2924034T3 (en)	2017-02-06
TW201139409A (en)	2011-11-16
NL300980I1 (nl)	2019-04-24
EP2924034B1 (en)	2016-11-02
BR112012024691B1 (pt)	2020-11-17
HUE025336T2 (en)	2016-03-29
HRP20150427T1 (hr)	2015-07-03
NO2019018I1 (no)	2019-04-24
RS54017B1 (sr)	2015-10-30
LTPA2019506I1 (lt)	2019-04-25
PE20130158A1 (es)	2013-02-28
CY2019025I1 (el)	2019-11-27
SI2924034T1 (sl)	2017-05-31
CY2019026I2 (el)	2020-05-29
HRP20161680T1 (hr)	2017-01-27
PT2552902E (pt)	2015-06-02
ES2609636T3 (es)	2017-04-21
SI2552902T1 (sl)	2015-10-30
MA34170B1 (fr)	2013-04-03
WO2011120133A1 (en)	2011-10-06
KR20120128703A (ko)	2012-11-27
JP2013209405A (ja)	2013-10-10
CN102971308B (zh)	2015-02-04
NI201200146A (es)	2013-03-18
CL2012002744A1 (es)	2012-12-14
BR112012024691A2 (pt)	2019-07-02
IL222030A (en)	2014-07-31
LTPA2019507I1 (lt)	2019-04-25
CY2019026I1 (el)	2020-05-29
LUC00114I2 (lt)	2020-07-10
PL2552902T3 (pl)	2015-10-30
JP5886790B2 (ja)	2016-03-16
MY163979A (en)	2017-11-15
US20130296382A1 (en)	2013-11-07
JP2013510800A (ja)	2013-03-28
LUC00114I1 (lt)	2019-04-17
CR20120503A (es)	2013-01-09
TN2012000455A1 (en)	2014-01-30
ES2536295T3 (es)	2015-05-22
AU2011235568A1 (en)	2012-11-01
US8486975B2 (en)	2013-07-16
NZ602670A (en)	2014-09-26
LUC00113I9 (lt)	2024-06-07

Publication	Publication Date	Title
LTPA2019507I1 (lt)	2019-04-25	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
SMT201600350B (it)	2016-11-10	Composizioni farmaceutiche
DK3192501T3 (da)	2020-08-03	Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BR112014001255A2 (pt)	2017-02-21	composto, uso de um composto, combinação, e, composição farmacêutica
DK4374878T3 (da)	2025-05-05	Farmaceutisk sammensætning, der omfatter carbetocin
DK4159204T3 (da)	2024-05-21	Hidtil ukendt farmaceutisk sammensætning
BR112013003536A2 (pt)	2016-06-28	composição, e utilização de uma composição.
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
EP2647381A4 (en)	2015-12-23	MELTING TABLET
EE201300005A (et)	2013-08-15	Ravimkoostis
DK3070091T3 (da)	2019-07-08	Benzodioxolderivater som phosphodiesterasehæmmere
IT1401989B1 (it)	2013-08-28	Espansore rapido palatale con dentino antiritorno
CO6801722A2 (es)	2013-11-29	Composiciones farmacéuticas
BR112013019518A2 (pt)	2018-07-10	composições para cuidado oral.
EP2612657A4 (en)	2014-05-07	MELTING TABLET
BR112013019061A2 (pt)	2018-06-26	composto inibidor da caspase-2, composição farmacêutica e uso de um composto
BR112012029461A2 (pt)	2017-03-01	composição farmacêutica contendo solifenacina
BR112012029887A2 (pt)	2016-08-16	composição farmacêutica
BR112014016122A8 (pt)	2017-07-04	composto, e, composição farmacêutica
BR112013022890A2 (pt)	2016-09-13	composto, composição farmacêutica, combinação e uso de um composto
BR112014001932A2 (pt)	2017-02-21	composto, composição farmacêutica, combinação de um composto e uso de um composto
IT1406067B1 (it)	2014-02-06	Composizioni eudermiche.
BR112013015813A2 (pt)	2018-05-29	composição.